Sun Pharma to Acquire InSite Vision
Sun Pharma has announced its one of the subsidiary entering into an agreement and plan of merger with InSite Vision […]
Say something
Tags: bacterial eye infections, Besifloxacin, BSE Sensex, Business/Finance, CEO, Chemistry, Cyclopropanes, drug delivery technology, DuraSite, DuraSite platform, health, Health/Medical/Pharmaceuticals, Insite, INSITE VISION INCORPORATED, Jerry St. Peter, Kal Sundaram, Latanoprost, M&A, ophthalmic products, ophthalmic solution, Organic chemistry, Organochlorides, owned subsidiary, Sun Pharmaceutical, SUN PHARMACEUTICAL INDUSTRIES LIMITED, United States, USD, Vice President and Head
Dr Reddys Inks commercialisation Deal with Hatchtech
Dr Reddy’s Laboratories has announced the signing of a commercialisation deal with Hatchtech, an Australian pharmaceutical company for developing an […]
Eli Lilly to Introduce New Diabetes Medication in India
Eli Lilly, a US-based pharma company is all set to launch a new medication to enhance its diabetes treatment […]
Pharma Organisations try to Drive Growth
Emerging markets are predicted to account for a third of global pharmaceutical spend by the end of next year and […]
Dr. Reddy announces Filing of Annual Report on Form 20-F
Dr. Reddys Laboratories Limited, an integrated pharmaceutical company, has announced that its Annual Report on Form 20-F, containing its annual […]
Cipla Signs JV with Moroccos Cooper Pharma and PHI
Cipla (EU) Ltd., a wholly-owned subsidiary of Mumbai based drug firm Cipla Ltd., has inked the joint venture agreement with […]
Sun Pharma hits record high
Shares of Sun Pharmaceutical Industries and Ranbaxy Laboratories are trading higher by 2 percent. Sun Pharma stock surged 2 percent […]
-
-
Flipkart Health+ App Launched
06-04-2022
